Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Bruce E. Brockstein

TitleCLINICAL ASSOCIATE PROFESSOR
InstitutionUniversity of Chicago
DepartmentMedicine
AddressChicago IL 60637
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Olson DJ, Eroglu Z, Brockstein B, Poklepovic AS, Bajaj M, Babu S, Hallmeyer S, Velasco M, Lutzky J, Higgs E, Bao R, Carll TC, Labadie B, Krausz T, Zha Y, Karrison T, Sondak VK, Gajewski TF, Khushalani NI, Luke JJ. Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma. J Clin Oncol. 2021 May 04; JCO2100079. PMID: 33945288.
      View in: PubMed
    2. Sullivan K, Kaminer LS, Grinblatt DL, Campbell NP, Nocon CC, Harper AJ, Kang JH, Sarav M, Curtis BR, Brockstein BE. Trastuzumab-Induced Thrombocytopenia Correlated by Drug-Dependent Platelet Antibodies. JCO Oncol Pract. 2021 Mar; 17(3):153-155. PMID: 33270522.
      View in: PubMed
    3. Gremore TM, Brockstein B, Porter LS, Brenner S, Benfield T, Baucom DH, Sher TG, Atkins D. Couple-based communication intervention for head and neck cancer: a randomized pilot trial. Support Care Cancer. 2021 Jun; 29(6):3267-3275. PMID: 33106976.
      View in: PubMed
    4. Paintal AS, Brockstein BE. PD-L1 CPS Scoring Accuracy in Small Biopsies and Aspirate Cell Blocks from Patients with Head and Neck Squamous Cell Carcinoma. Head Neck Pathol. 2020 Sep; 14(3):657-665. PMID: 31721075.
      View in: PubMed
    5. Jones RL, Ratain MJ, O'Dwyer PJ, Siu LL, Jassem J, Medioni J, DeJonge M, Rudin C, Sawyer M, Khayat D, Awada A, de Vos-Geelen JMPGM, Evans TRJ, Obel J, Brockstein B, DeGreve J, Baurain JF, Maki R, D'Adamo D, Dickson M, Undevia S, Geary D, Janisch L, Bedard PL, Abdul Razak AR, Kristeleit R, Vitfell-Rasmussen J, Walters I, Kaye SB, Schwartz G. Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours. Eur J Cancer. 2019 10; 120:132-139. PMID: 31522033.
      View in: PubMed
    6. Chugh R, Griffith KA, Davis EJ, Thomas DG, Zavala JD, Metko G, Brockstein B, Undevia SD, Stadler WM, Schuetze SM. Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model. Ann Oncol. 2019 08 01; 30(8):1405. PMID: 30726873.
      View in: PubMed
    7. Finkle JH, Penney BC, Pu Y. An updated and validated PET/CT volumetric prognostic index for non-small cell lung cancer. Lung Cancer. 2018 09; 123:136-141. PMID: 10986067.
      View in: PubMed
    8. Ajmani GS, Nocon CC, Brockstein BE, Campbell NP, Kelly AB, Allison J, Bhayani MK. Association of a Proactive Swallowing Rehabilitation Program With Feeding Tube Placement in Patients Treated for Pharyngeal Cancer. JAMA Otolaryngol Head Neck Surg. 2018 06 01; 144(6):483-488. PMID: 29710108.
      View in: PubMed
    9. de Souza JA, Yap BJ, Wroblewski K, Blinder V, Araújo FS, Hlubocky FJ, Nicholas LH, O'Connor JM, Brockstein B, Ratain MJ, Daugherty CK, Cella D. Measuring financial toxicity as a clinically relevant patient-reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST). Cancer. 2017 02 01; 123(3):476-484. PMID: 27716900.
      View in: PubMed
    10. Shah S, Ward JE, Bao R, Hall CR, Brockstein BE, Luke JJ. Clinical Response of a Patient to Anti-PD-1 Immunotherapy and the Immune Landscape of Testicular Germ Cell Tumors. Cancer Immunol Res. 2016 11; 4(11):903-909. PMID: 27638840.
      View in: PubMed
    11. Campbell NP, Hensing TA, Bhayani MK, Shaikh AY, Brockstein BE. Targeting pathways mediating resistance to anti-EGFR therapy in squamous cell carcinoma of the head and neck. Expert Rev Anticancer Ther. 2016 Aug; 16(8):847-58. PMID: 27400139.
      View in: PubMed
    12. Soto Chervin C, Brockstein B. Current clinical immunotherapeutic approaches for head and neck cancer. F1000Res. 2016; 5. PMID: 27239282.
      View in: PubMed
    13. Chandar M, Brockstein B, Zunamon A, Silverman I, Dlouhy S, Ashlevitz K, Tabachow C, Lapin B, Ewigman B, Mazzone T, Obel J. Perspectives of Health-Care Providers Toward Advance Care Planning in Patients With Advanced Cancer and Congestive Heart Failure. Am J Hosp Palliat Care. 2017 Jun; 34(5):423-429. PMID: 26941370.
      View in: PubMed
    14. Rosenberg CA, Flanagan C, Brockstein B, Obel JC, Dragon LH, Merkel DE, Wade EL, Law TM, Khandekar JD, Hensing TA. Promotion of self-management for post treatment cancer survivors: evaluation of a risk-adapted visit. J Cancer Surviv. 2016 Feb; 10(1):206-19. PMID: 26178325.
      View in: PubMed
    15. Liederbach E, Lewis CM, Yao K, Brockstein BE, Wang CH, Lutfi W, Bhayani MK. A Contemporary Analysis of Surgical Trends in the Treatment of Squamous Cell Carcinoma of the Oropharynx from 1998 to 2012: A Report from the National Cancer Database. Ann Surg Oncol. 2015 Dec; 22(13):4422-31. PMID: 25893414.
      View in: PubMed
    16. Chugh R, Griffith KA, Davis EJ, Thomas DG, Zavala JD, Metko G, Brockstein B, Undevia SD, Stadler WM, Schuetze SM. Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model. Ann Oncol. 2015 07; 26(7):1459-64. PMID: 25858498.
      View in: PubMed
    17. Cohen EE, Kocherginsky M, Karrison T, Seiwert TY, Haraf DJ, Brockstein B, Vokes EE. Reply to s. Chakraborty et al. J Clin Oncol. 2015 Mar 10; 33(8):968. PMID: 25667282.
      View in: PubMed
    18. Obel J, Brockstein B, Marschke M, Robicsek A, Konchak C, Sefa M, Ziomek N, Benfield T, Peterson C, Gustafson C, Eriksson J, Harper A, Tabachow C, Raymond M, Hensing T. Outpatient advance care planning for patients with metastatic cancer: a pilot quality improvement initiative. J Palliat Med. 2014 Nov; 17(11):1231-7. PMID: 25343403.
      View in: PubMed
    19. Cohen EE, Karrison TG, Kocherginsky M, Mueller J, Egan R, Huang CH, Brockstein BE, Agulnik MB, Mittal BB, Yunus F, Samant S, Raez LE, Mehra R, Kumar P, Ondrey F, Marchand P, Braegas B, Seiwert TY, Villaflor VM, Haraf DJ, Vokes EE. Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. J Clin Oncol. 2014 Sep 01; 32(25):2735-43. PMID: 25049329.
      View in: PubMed
    20. Clarke M, Ortel B, Brockstein B, Rojanapremsuk T, Victor T, Thomas A, Cibull T. Bilateral areolar leiomyomas in a patient undergoing BRAF inhibition therapy for melanoma. J Cutan Pathol. 2013 Oct; 40(10):884-6. PMID: 23924408.
      View in: PubMed
    21. Schwartz GK, Tap WD, Qin LX, Livingston MB, Undevia SD, Chmielowski B, Agulnik M, Schuetze SM, Reed DR, Okuno SH, Ludwig JA, Keedy V, Rietschel P, Kraft AS, Adkins D, Van Tine BA, Brockstein B, Yim V, Bitas C, Abdullah A, Antonescu CR, Condy M, Dickson MA, Vasudeva SD, Ho AL, Doyle LA, Chen HX, Maki RG. Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial. Lancet Oncol. 2013 Apr; 14(4):371-82. PMID: 23477833.
      View in: PubMed
    22. Fury MG, Sherman E, Lisa D, Agarwal N, Algazy K, Brockstein B, Langer C, Lim D, Mehra R, Rajan SK, Korte S, Lipson B, Yunus F, Tanvetyanon T, Smith-Marrone S, Ng K, Xiao H, Haque S, Pfister DG. A randomized phase II study of cetuximab every 2 weeks at either 500 or 750 mg/m2 for patients with recurrent or metastatic head and neck squamous cell cancer. J Natl Compr Canc Netw. 2012 Nov 01; 10(11):1391-8. PMID: 23138167.
      View in: PubMed
    23. Agulnik M, Yarber JL, Okuno SH, von Mehren M, Jovanovic BD, Brockstein BE, Evens AM, Benjamin RS. An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann Oncol. 2013 Jan; 24(1):257-63. PMID: 22910841.
      View in: PubMed
    24. Wali RK, Kunte DP, De La Cruz M, Tiwari AK, Brasky J, Weber CR, Gibson TP, Patel A, Savkovic SD, Brockstein BE, Roy HK. Topical polyethylene glycol as a novel chemopreventive agent for oral cancer via targeting of epidermal growth factor response. PLoS One. 2012; 7(6):e38047. PMID: 22675506.
      View in: PubMed
    25. Brockstein BE. Management of recurrent head and neck cancer: recent progress and future directions. Drugs. 2011 Aug 20; 71(12):1551-9. PMID: 21861540.
      View in: PubMed
    26. Harshberger CA, Harper AJ, Carro GW, Spath WE, Hui WC, Lawton JM, Brockstein BE. Outcomes of computerized physician order entry in an electronic health record after implementation in an outpatient oncology setting. J Oncol Pract. 2011 Jul; 7(4):233-7. PMID: 22043187.
      View in: PubMed
    27. Brockstein B, Hensing T, Carro GW, Obel J, Khandekar J, Kaminer L, Van De Wege C, de Wilton Marsh R. Effect of an electronic health record on the culture of an outpatient medical oncology practice in a four-hospital integrated health care system: 5-year experience. J Oncol Pract. 2011 Jul; 7(4):e20-4. PMID: 22043197.
      View in: PubMed
    28. Brockstein BE, Vokes EE. Head and neck cancer in 2010: Maximizing survival and minimizing toxicity. Nat Rev Clin Oncol. 2011 Feb; 8(2):72-4. PMID: 21278773.
      View in: PubMed
    29. Brockstein B, Vokes EE. Radiotherapy: Accelerated radiotherapy for HNSCC in developing countries. Nat Rev Clin Oncol. 2010 Nov; 7(11):616-8. PMID: 20981124.
      View in: PubMed
    30. Cohen EE, Haraf DJ, Kunnavakkam R, Stenson KM, Blair EA, Brockstein B, Lester EP, Salama JK, Dekker A, Williams R, Witt ME, Grushko TA, Dignam JJ, Lingen MW, Olopade OI, Vokes EE. Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol. 2010 Jul 10; 28(20):3336-43. PMID: 20498391.
      View in: PubMed
    31. Argiris A, Buchanan A, Brockstein B, Kolesar J, Ghebremichael M, Pins M, Hahn K, Axelrod R, Forastiere A. Docetaxel and irinotecan in recurrent or metastatic head and neck cancer: a phase 2 trial of the Eastern Cooperative Oncology Group. Cancer. 2009 Oct 01; 115(19):4504-13. PMID: 19634157.
      View in: PubMed
    32. Maki RG, D'Adamo DR, Keohan ML, Saulle M, Schuetze SM, Undevia SD, Livingston MB, Cooney MM, Hensley ML, Mita MM, Takimoto CH, Kraft AS, Elias AD, Brockstein B, Blachère NE, Edgar MA, Schwartz LH, Qin LX, Antonescu CR, Schwartz GK. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol. 2009 Jul 01; 27(19):3133-40. PMID: 19451436.
      View in: PubMed
    33. Lal A, Brockstein B, Grinblatt D. Review: coagulopathy and factor inhibitors. Clin Adv Hematol Oncol. 2008 Dec; 6(12):925-7. PMID: 19209143.
      View in: PubMed
    34. Brockstein B, Lacouture M, Agulnik M. The role of inhibitors of the epidermal growth factor in management of head and neck cancer. J Natl Compr Canc Netw. 2008 Aug; 6(7):696-706. PMID: 18691458.
      View in: PubMed
    35. Head and neck cancers. J Natl Compr Canc Netw. 2008 Aug; 6(7):646-95. PMID: 18691457.
      View in: PubMed
    36. Salama JK, Stenson KM, Kistner EO, Mittal BB, Argiris A, Witt ME, Rosen F, Brockstein BE, Cohen EE, Haraf DJ, Vokes EE. Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levels. Ann Oncol. 2008 Oct; 19(10):1787-94. PMID: 18539617.
      View in: PubMed
    37. Yount S, List M, Du H, Yost K, Bode R, Brockstein B, Argiris A, Vokes E, Cohen EE, Campbell B, Valenzuela V, George J, Egan R, Chen J, Meddis D, Cella D. A randomized validation study comparing embedded versus extracted FACT Head and Neck Symptom Index scores. Qual Life Res. 2007 Dec; 16(10):1615-26. PMID: 17922221.
      View in: PubMed
    38. Cohen EE, Haraf DJ, List MA, Kocherginsky M, Mittal BB, Rosen F, Brockstein B, Williams R, Witt ME, Stenson KM, Kies MS, Vokes EE. High survival and organ function rates after primary chemoradiotherapy for intermediate-stage squamous cell carcinoma of the head and neck treated in a multicenter phase II trial. J Clin Oncol. 2006 Jul 20; 24(21):3438-44. PMID: 16849759.
      View in: PubMed
    39. Carneiro BA, Watkin WG, Mehta UK, Brockstein BE. Metastatic basal cell carcinoma: complete response to chemotherapy and associated pure red cell aplasia. Cancer Invest. 2006 Jun-Jul; 24(4):396-400. PMID: 16777692.
      View in: PubMed
    40. Logemann JA, Rademaker AW, Pauloski BR, Lazarus CL, Mittal BB, Brockstein B, MacCracken E, Haraf DJ, Vokes EE, Newman LA, Liu D. Site of disease and treatment protocol as correlates of swallowing function in patients with head and neck cancer treated with chemoradiation. Head Neck. 2006 Jan; 28(1):64-73. PMID: 16302193.
      View in: PubMed
    41. Cohen EE, Kane MA, List MA, Brockstein BE, Mehrotra B, Huo D, Mauer AM, Pierce C, Dekker A, Vokes EE. Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res. 2005 Dec 01; 11(23):8418-24. PMID: 16322304.
      View in: PubMed
    42. Cohen EE, Haraf DJ, Stenson KM, Blair E, Brockstein BE, Mauer AM, Dekker A, Williams R, Lester E, Vokes EE. Integration of gefitinib (G), into a concurrent chemoradiation (CRT) regimen followed by G adjuvant therapy in patients with locally advanced head and neck cancer (HNC) - a Phase II Trial. J Clin Oncol. 2005 Jun; 23(16_suppl):5506. PMID: 27945467.
      View in: PubMed
    43. Argiris A, Goldwasser MA, Brockstein B, Axelrod R, Forastiere A. Weekly docetaxel (D) and irinotecan (I) in patients (pts) with recurrent or metastatic head and neck cancer (HNC): A phase II trial of the Eastern Cooperative Oncology Group (ECOG). J Clin Oncol. 2005 Jun; 23(16_suppl):5528. PMID: 27945241.
      View in: PubMed
    44. Forastiere AA, Ang K, Brizel D, Brockstein BE, Dunphy F, Eisele DW, Goepfert H, Hicks WL, Kies MS, Lydiatt WM, Maghami E, McCaffrey T, Mittal BB, Pfister DG, Pinto HA, Posner MR, Ridge JA, Samant S, Schuller DE, Shah JP, Spencer S, Trotti A, Wheeler RH, Wolf GT, Worden F, Yueh B. Head and neck cancers. J Natl Compr Canc Netw. 2005 May; 3(3):316-91. PMID: 16002004.
      View in: PubMed
    45. Brockstein BE. Metastatic osteosarcoma: a curable advanced malignancy. J Clin Oncol. 2004 Dec 15; 22(24):5017; author reply 5017-8. PMID: 15611520.
      View in: PubMed
    46. Brockstein B, Vokes EE. Concurrent chemoradiotherapy for head and neck cancer. Semin Oncol. 2004 Dec; 31(6):786-93. PMID: 15599856.
      View in: PubMed
    47. Brockstein B, Haraf DJ, Rademaker AW, Kies MS, Stenson KM, Rosen F, Mittal BB, Pelzer H, Fung BB, Witt ME, Wenig B, Portugal L, Weichselbaum RW, Vokes EE. Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience. Ann Oncol. 2004 Aug; 15(8):1179-86. PMID: 15277256.
      View in: PubMed
    48. Brockstein B. Management of sarcomas of the head and neck. Curr Oncol Rep. 2004 Jul; 6(4):321-7. PMID: 15161589.
      View in: PubMed
    49. Argiris A, Stenson KM, Brockstein BE, Mittal BB, Pelzer H, Kies MS, Jayaram P, Portugal L, Wenig BL, Rosen FR, Haraf DJ, Vokes EE. Neck dissection in the combined-modality therapy of patients with locoregionally advanced head and neck cancer. Head Neck. 2004 May; 26(5):447-55. PMID: 15122662.
      View in: PubMed
    50. Argiris A, Brockstein BE, Haraf DJ, Stenson KM, Mittal BB, Kies MS, Rosen FR, Jovanovic B, Vokes EE. Competing causes of death and second primary tumors in patients with locoregionally advanced head and neck cancer treated with chemoradiotherapy. Clin Cancer Res. 2004 Mar 15; 10(6):1956-62. PMID: 15041712.
      View in: PubMed
    51. Haraf DJ, Rosen FR, Stenson K, Argiris A, Mittal BB, Witt ME, Brockstein BE, List MA, Portugal L, Pelzer H, Weichselbaum RR, Vokes EE. Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer. Clin Cancer Res. 2003 Dec 01; 9(16 Pt 1):5936-43. PMID: 14676118.
      View in: PubMed
    52. Lamont EB, Hayreh D, Pickett KE, Dignam JJ, List MA, Stenson KM, Haraf DJ, Brockstein BE, Sellergren SA, Vokes EE. Is patient travel distance associated with survival on phase II clinical trials in oncology? J Natl Cancer Inst. 2003 Sep 17; 95(18):1370-5. PMID: 13130112.
      View in: PubMed
    53. Rosen FR, Haraf DJ, Kies MS, Stenson K, Portugal L, List MA, Brockstein BE, Mittal BB, Rademaker AW, Witt ME, Pelzer H, Weichselbaum RR, Vokes EE. Multicenter randomized Phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer. Clin Cancer Res. 2003 May; 9(5):1689-97. PMID: 12738722.
      View in: PubMed
    54. Vokes EE, Stenson K, Rosen FR, Kies MS, Rademaker AW, Witt ME, Brockstein BE, List MA, Fung BB, Portugal L, Mittal BB, Pelzer H, Weichselbaum RR, Haraf DJ. Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer. J Clin Oncol. 2003 Jan 15; 21(2):320-6. PMID: 12525525.
      View in: PubMed
    55. Brockstein B. Organ preservation for advanced head and neck cancer concomitant chemoradiation. Cancer Treat Res. 2003; 114:235-48. PMID: 12619544.
      View in: PubMed
    56. Masters GA, Brockstein BE, Mani S, Ratain MJ. Phase 1 dose escalation study of docetaxel with filgrastim support in patients with advanced solid tumors. Med Oncol. 2003; 20(1):7-12. PMID: 12665678.
      View in: PubMed
    57. Brockstein B, Mundt A, Haraf DJ, Ferguson M, Montag A. Radiation-induced leiomyosarcoma: does antimetabolite chemotherapy contribute? A report of three cases. Sarcoma. 2003; 7(3-4):167-72. PMID: 18521382.
      View in: PubMed
    58. Masters G, Brockstein B. Overview of head and neck cancer. Cancer Treat Res. 2003; 114:1-13. PMID: 12619536.
      View in: PubMed
    59. Sener SF, Milos S, Feldman JL, Martz CH, Winchester DJ, Dieterich M, Locker GY, Khandekar JD, Brockstein B, Haid M, Michel A. The spectrum of vascular lesions in the mammary skin, including angiosarcoma, after breast conservation treatment for breast cancer. J Am Coll Surg. 2001 Jul; 193(1):22-8. PMID: 11442250.
      View in: PubMed
    60. Kies MS, Haraf DJ, Rosen F, Stenson K, List M, Brockstein B, Chung T, Mittal BB, Pelzer H, Portugal L, Rademaker A, Weichselbaum R, Vokes EE. Concomitant infusional paclitaxel and fluorouracil, oral hydroxyurea, and hyperfractionated radiation for locally advanced squamous head and neck cancer. J Clin Oncol. 2001 Apr 01; 19(7):1961-9. PMID: 11283128.
      View in: PubMed
    61. Brockstein B, Samuels B, Humerickhouse R, Arietta R, Fishkin P, Wade J, Sosman J, Vokes EE. Phase II studies of bryostatin-1 in patients with advanced sarcoma and advanced head and neck cancer. Invest New Drugs. 2001; 19(3):249-54. PMID: 11561683.
      View in: PubMed
    62. Pfister DG, Ang K, Brockstein B, Colevas AD, Ellenhorn J, Goepfert H, Hicks WL, Hong WK, Kies MS, Lydiatt W, McCaffrey T, Mittal BB, Ridge JA, Schuller DE, Shah JP, Spencer S, Trotti A, Urba S, Weymuller EA, Wheeler RH, Wolf GT. NCCN Practice Guidelines for Head and Neck Cancers. Oncology (Williston Park). 2000 Nov; 14(11A):163-94. PMID: 11195409.
      View in: PubMed
    63. Brockstein B. Benefits of chemotherapy in head and neck cancer. Lancet. 2000 Aug 26; 356(9231):767-8. PMID: 11085713.
      View in: PubMed
    64. Lad T, Rosen F, Sciortino D, Brockstein B, Keubler JP, Arietta R, Vokes E. Phase II trial of aminocamptothecin (9-AC/DMA) in patients with advanced squamous cell head and neck cancer. Invest New Drugs. 2000 Aug; 18(3):261-3. PMID: 10958595.
      View in: PubMed
    65. Brockstein B, Haraf DJ, Stenson K, Sulzen L, Witt ME, Weichselbaum RW, Vokes EE. A phase I-II study of concomitant chemoradiotherapy with paclitaxel (one-hour infusion), 5-fluorouracil and hydroxyurea with granulocyte colony stimulating factor support for patients with poor prognosis head and neck cancer. Ann Oncol. 2000 Jun; 11(6):721-8. PMID: 10942062.
      View in: PubMed
    66. Brockstein B. Integration of taxanes into primary chemotherapy for squamous cell carcinoma of the head and neck: promise fulfilled? Curr Opin Oncol. 2000 May; 12(3):221-8. PMID: 10841194.
      View in: PubMed
    67. Brockstein BE, Smiley C, Al-Sadir J, Williams SF. Cardiac and pulmonary toxicity in patients undergoing high-dose chemotherapy for lymphoma and breast cancer: prognostic factors. Bone Marrow Transplant. 2000 Apr; 25(8):885-94. PMID: 10808211.
      View in: PubMed
    68. Stenson KM, MacCracken E, List M, Haraf DJ, Brockstein B, Weichselbaum R, Vokes EE. Swallowing function in patients with head and neck cancer prior to treatment. Arch Otolaryngol Head Neck Surg. 2000 Mar; 126(3):371-7. PMID: 10722011.
      View in: PubMed
    69. Wolf GT, Forastiere A, Ang K, Brockstein B, Conley B, Goepfert H, Kraus D, Lefebvre JL, Pajak TF, Pfister D, Urba S. Workshop report: organ preservation strategies in advanced head and neck cancer--current status and future directions. Head Neck. 1999 Dec; 21(8):689-93. PMID: 10562680.
      View in: PubMed
    70. Vokes EE, Haraf DJ, Brockstein BE, Weichselbaum RR. Paclitaxel, 5-fluorouracil, hydroxyurea, and concomitant radiation therapy for poor-prognosis head and neck cancer. Semin Radiat Oncol. 1999 Apr; 9(2 Suppl 1):70-6. PMID: 10210543.
      View in: PubMed
    71. Humerickhouse RA, Dolan ME, Haraf DJ, Brockstein B, Stenson K, Kies M, Sulzen L, Ratain MJ, Vokes EE. Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer. Clin Cancer Res. 1999 Feb; 5(2):291-8. PMID: 10037177.
      View in: PubMed
    72. Brockstein BE, Vokes EE. Oral chemotherapy in head and neck cancer. Drugs. 1999; 58 Suppl 3:91-7. PMID: 10711847.
      View in: PubMed
    73. Lamont EB, Cavaghan MK, Brockstein BE. Oncogenic osteomalacia as a harbinger of recurrent osteosarcoma. Sarcoma. 1999; 3(2):95-9. PMID: 18521270.
      View in: PubMed
    74. Vokes EE, Brockstein BE, Humerickhouse R, Haraf DJ. Oral 5-FU alternatives for the treatment of head and neck cancer. Oncology (Williston Park). 1998 Oct; 12(10 Suppl 7):35-8. PMID: 9830623.
      View in: PubMed
    75. Vogelzang NJ, Mani S, Schilsky RL, Ansari RH, Taber D, Rhinehart SN, Garcia JC, Meyer SC, Mick R, Brockstein BE, Stadler WM, Ratain MJ, Vokes EE. Phase II and pharmacodynamic studies of pyrazine diazohydroxide (NSC 361456) in patients with advanced renal and colorectal cancer. Clin Cancer Res. 1998 Apr; 4(4):929-34. PMID: 9563886.
      View in: PubMed
    76. Brockstein B, Haraf DJ, Stenson K, Fasanmade A, Stupp R, Glisson B, Lippman SM, Ratain MJ, Sulzen L, Klepsch A, Weichselbaum RR, Vokes EE. Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck. J Clin Oncol. 1998 Feb; 16(2):735-44. PMID: 9469365.
      View in: PubMed
    77. Brockstein BE, Ross AA, Moss TJ, Kahn DG, Hollingsworth K, Williams SF. Tumor cell contamination of bone marrow harvest products: clinical consequences in a cohort of advanced-stage breast cancer patients undergoing high-dose chemotherapy. J Hematother. 1996 Dec; 5(6):617-24. PMID: 9117250.
      View in: PubMed
    78. Brockstein BE, Williams SF. High-dose chemotherapy with autologous stem cell rescue for breast cancer: yesterday, today and tomorrow. Stem Cells. 1996 Jan; 14(1):79-89. PMID: 8820954.
      View in: PubMed
    79. Brockstein B, Johns L, Gewertz BL. Blood supply to the spinal cord: anatomic and physiologic correlations. Ann Vasc Surg. 1994 Jul; 8(4):394-9. PMID: 7947069.
      View in: PubMed
    Brockstein's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (256) concept(s)
    _
    Co-Authors Expand Description
    See all (43) people
    _
    Similar People Expand Description
    See all (60) people
    _
    Same Department Expand Description
    Search Department
    Physical Neighbors Expand Description
    _